Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Matsui

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
The Journal of Clinical Investigation|January 4, 2007
Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistanceYasuo Terauchi, Iseki Takamoto, Naoto Kubota, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Therapy. Nucleic Acids|March 3, 2025
<i>In vivo</i> production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infectionYuta Suzuki, Takayuki Miyazaki, Yoko Ida, et al.
Molecular Cancer Therapeutics|August 19, 2016
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical ModelsSaori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, et al.
The Journal of Biological Chemistry|November 15, 2002
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosisToshimasa Yamauchi, Junji Kamon, Hironori Waki, et al.
Molecular Cancer Therapeutics|October 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic DrugsShuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, et al.
Vascular Cell|September 9, 2014
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageYuji Yamamoto, Junji Matsui, Tomohiro Matsushima, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
The Journal of Clinical Investigation|January 4, 2007
Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistanceYasuo Terauchi, Iseki Takamoto, Naoto Kubota, et al.
Journal for Immunotherapy of Cancer|January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Therapy. Nucleic Acids|March 3, 2025
<i>In vivo</i> production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infectionYuta Suzuki, Takayuki Miyazaki, Yoko Ida, et al.
Molecular Cancer Therapeutics|August 19, 2016
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical ModelsSaori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, et al.
The Journal of Biological Chemistry|November 15, 2002
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosisToshimasa Yamauchi, Junji Kamon, Hironori Waki, et al.
Molecular Cancer Therapeutics|October 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic DrugsShuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, et al.
Vascular Cell|September 9, 2014
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageYuji Yamamoto, Junji Matsui, Tomohiro Matsushima, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Pageof 7